These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2691569

  • 1. Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses.
    Porres JC, Carreño V, Bartolomé J, Moreno A, Galiana F, Quiroga JA.
    J Hepatol; 1989 Nov; 9(3):338-44. PubMed ID: 2691569
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prolonged alpha interferon therapy for chronic delta hepatitis: effect on liver histopathology.
    Kleiner D, Di Bisceglie AM, Axiotis CA, Hoofnagle JH.
    Prog Clin Biol Res; 1993 Nov; 382():365-71. PubMed ID: 8502705
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study.
    Rosina F, Pintus C, Meschievitz C, Rizzetto M.
    Hepatology; 1991 Jun; 13(6):1052-6. PubMed ID: 2050321
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A.
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and serological outcome of acute delta infection.
    Buti M, Estebán R, Jardi R, Allende H, Estebán JI, Genesca J, Guardia J.
    J Hepatol; 1987 Aug; 5(1):59-64. PubMed ID: 3655311
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Natural killer cell function during interferon treatment of delta hepatitis.
    Actis GC, Maran E, Saracco G, Rosina F, Baldi M, Brunetto M.
    Prog Clin Biol Res; 1987 Aug; 234():305-8. PubMed ID: 3628385
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Natural killer response to exogenous interferon in delta hepatitis: boost or depression defined within the first week of therapy.
    Actis GC, Maran E, Rosina F, Saracco G, Rocca G, Rizzetto M, Bonino F, Verme G.
    Digestion; 1987 Aug; 37(1):51-8. PubMed ID: 3609505
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.